| Business Summary | | Applied
Molecular
Evolution
Inc.
is
engaged
in
the
application
of
directed
evolution
to
the
development
of
biotherapeutics.
Directed
evolution
is
a
process
for
optimizing
genes
and
proteins
for
specific
commercial
purposes.
The
Company
uses
its
proprietary
AMEsystem
technology
to
rapidly
create
protein
improvements,
which
would
be
too
inefficient
and
expensive
to
achieve
through
conventional
methods.
The
Company
plans
to
use
its
directed
evolution
technology
to
develop
improved
versions
of
marketed,
FDA-approved
biopharmaceuticals,
as
well
as
novel
human
biotherapeutics.
The
components
of
the
AMEsystem,
DirectAME,
ExpressAME
and
SelectAME,
are
designed
to
be
precise
and
efficient
methods
for
conducting
the
three
fundamental
steps
of
directed
evolution
and
address
the
limitations
of
alternative
directed-evolution
approaches. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Applied
Molecular
Evolution
utilizes
directed
evolution
technology
to
develop
improved
versions
of
currently
marketed,
FDA-approved
drugs
as
well
as
novel
human
therapeutics.
For
the
six
months
ended
6/30/01,
revenues
rose
34%
to
$1.6
million.
Net
loss
applicable
to
Common
fell
60%
to
$6.7
million.
Revenues
reflect
increased
corporate
NIH
grants,
collaboration
and
Kauffman
patent
licencing.
Net
loss
also
reflects
the
absence
of
series
F
preferred
dividends. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Costa Sevastopoulos, Ph.D., 57 Chairman | -- | William Huse, M.D., Ph.D., 46 Pres,
CEO, Director | $335K | Lawrence Bloch, M.D., 35 CFO,
VP-Bus. Devel., Sec. | 182K | Jeffry Watkins, Ph.D., 39 VP
of Research | 176K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|